Monday, August 11, 1997
Netherlands Emerging Company Profile
One of the roadblocks to development of adenovirus and adeno-associated virus as gene therapy vectors has been manufacturing. For adenovirus, the problem has been difficulty in manufacturing vectors free from contamination by replication-competent adenovirus. For adeno-associated virus, the issue has been the lack of a stable packaging cell line.
One company that believes it has solved the problems is IntroGene B.V., which is developing gene therapies based on adenoviral and AAV vectors, retroviral vectors and modified hematopoietic stem cells.